(1991; 44 pages) [French] [Spanish]
Ethionamide and protionamide
Group: antileprosy agent
Tablet 125 mg, 250 mg
The thioamides ethionamide and protionamide are derivatives of thioisonicotinic acid. Both are weakly bactericidal to M. leprae. Their biological properties and therapeutic potency are very similar.
They are readily absorbed from the gastrointestinal tract and widely distributed throughout body tissues. The plasma half-life of both compounds is approximately 2-4 hours and they are excreted in the urine largely as metabolites.
Treatment of multibacillary leprosy (in combination with dapsone and rifampicin), to prevent emergence of drug resistance. Because of their hepatotoxicity thioamides should be used only when clofazimine is unacceptable or not available.
Dosage and administration
Adults and children: 5.0 mg/kg daily (usual adult dose 250-375 mg).
• Known hypersensitivity.
• Hepatic dysfunction.
Liver function tests must be performed at the start of treatment and repeated periodically throughout.
Liver dysfunction and toxic hepatitis may occur.
Gastrointestinal disturbances are common. Other reported adverse effects include acne, allergic reactions, alopecia, convulsions, dermatitis, diplopia, dizziness, headache, hypotension, peripheral neuropathy and rheumatic pains.
Ethionamide and protionamide tablets should be kept in tightly closed containers protected from light.